Carbon nanomaterials as contrast agents for breast cancer diagnosis and therapy
- 370 Downloads
KeywordsBreast Cancer Breast Cancer Contrast Agent Breast Cancer Diagnosis Imaging Performance
Nanotechnology is the promise to fight breast cancer (BC) more specifically and effectively . In this context carbon nanomaterials (CNs) have attracted the scientific community and the public interest . Common modalities for BC diagnosis are ultrasonography (US) and magnetic resonance imaging (MRI). US is the most useful modality in the evaluation of palpable BC masses that are mammographically occult in women younger than 30’s. Here we show CNs as highly and long lasting echogenic materials. Experiments on swine models confirmed that CNs are clearly visible under US and didn’t exert toxicity. In the current market dual-imaging agents are missed; here we also demonstrate the immune-compatibility and high echogenic properties in water and in whole blood of cysteine functionalized super paramagnetic nanoparticles (CY-SPION), well-known MRI agents . Thanks to these findings, and the ability to load CNs to many moieties [4, 5, 6], we propose dual-contrast agents, CNs-CY-SPION conjugates, to improve BC diagnosis. Future perspectives is to conjugate CN-SPION to targeted drugs against BC. In summary, we lay the foundations for novel contrast agents, for therapy and multimodal diagnosis of BC, combining high imaging performances with unique potential therapeutic applications, such as specific targeting capabilities, drug delivery, immunotherapy and hyperthermia.
- 1.Avitabile E, Bedognetti D, Sgarella F, Delogu LG: Nanotechnology fight for breast cancer. (under preparation)Google Scholar
- 3.Dolci A, Ierardic V, Gradi A, Jagli Z, Remskard M, Apihd T, Cifellia M, Pampalonia G, Veracinia CA, Domenici V: Precursors of Magnetic Resonance Imaging Contrast Agents Based on Cystine-coated Iron-oxide Nanoparticles. Current Physical Chemistry. 2013, 3 (4): 493-500. 10.2174/18779468113036660009.CrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.